Masimo Foundation Co-Founds United for Oxygen Alliance
September 24 2016 - 6:25PM
Business Wire
Groundbreaking Public-Private Partnership to
Increase Access to Oxygen and Pulse Oximetry Launched at Clinton
Global Initiative
Masimo (NASDAQ: MASI) announced today that the Masimo
Foundation has co-founded the United for Oxygen Alliance, as part
of a Clinton Global Initiative (CGI) commitment. The
first-of-its-kind public-private partnership, announced this week
at the final CGI Annual Meeting, will seek to expand access to
medical oxygen and pulse oximetry for women and children in
Ethiopia. Other partners in the Alliance, which has fifteen members
in total, include the Bill & Melinda Gates Foundation (BMGF),
the United Nations, PATH, Philips, the Pneumonia Innovations Team,
Save the Children, UNICEF, and USAID.
Lack of medical oxygen access contributes to the deaths of more
than 120,000 young children and thousands of pregnant women,
globally, each year. It is estimated that in Ethiopia alone, each
year 11,000 women die in pregnancy or during childbirth, 60,000
babies die in their first month, and 30,000 children die from
pneumonia.1,2 Many of these deaths could be prevented by better
access to medical oxygen and reliable pulse oximetry technology.3
An oxygen access agenda is central to that of the Ethiopian
government, which has made it a part of their 2015-2020 Health
Sector Transformation Plan and National Newborn and Child Survival
Strategy.
United for Oxygen will partner with the Ethiopian government to
increase availability of pulse oximetry screenings and oxygen
therapy technologies across the country. In addition, it will
provide training for local staff; establish sustainable financial
solutions for procuring, installing, and maintaining equipment; and
promote oxygen access and technologies in the policies and
guidelines of Ethiopian health authorities. After the pilot
program, the Alliance hopes to roll out similar medical oxygen and
pulse oximetry programs in other countries where women and children
are particularly at risk.
Leith Greenslade, Co-Chair of the Pneumonia Innovations Team,
commented, “United for Oxygen is the first time companies and
development agencies have joined forces to support a government to
increase access to pulse oximetry and oxygen therapy across an
entire African nation - in this case Ethiopia. My hope is that we
will demonstrate that not only can pulse oximetry and oxygen
prevent many more Ethiopian children from dying of pneumonia, but
that health systems that routinely provide pulse oximetry screening
and oxygen will be much more effective at driving down death rates
from childbirth, unsafe surgery, cardiac arrest and injury.”
Masimo, as a global leader in noninvasive monitoring
technologies and whose SET® Measure-through Motion and Low
Perfusion™ pulse oximetry technology is estimated to be used on
more than 100 million patients around the world, will be
responsible for improving the availability of pulse oximetry in
hospitals and health centers, particularly in maternity and
pediatric units. Masimo’s role in United for Oxygen will also
include developing an efficient, effective health screening model
to prevent, detect, and treat pneumonia, as well as collaborating
on recommendations for sustaining the program post-deployment
through training, education, and maintenance.
Rasa Izadnegahdar, Senior Program Officer on the Pneumonia Team,
BMGF, noted, “Masimo is uniquely positioned to provide leadership
in the introduction of innovative life-saving devices in
partnership with countries as recently exemplified by the Oxygen
Roadmap of the Ethiopia Federal Ministry of Health.”
“This cannot be overstated: regardless of where you live or were
born, you deserve access to quality healthcare—including the
life-saving benefits of reliable pulse oximetry and oxygen
therapy,” said Joe Kiani, Founder and CEO of Masimo. “Masimo
continues to champion systematically safe, dignified health care
for all, and we are proud for the Masimo Foundation to be one of
the founding members of United for Oxygen. We look forward to
collaborating further on this important project.”
@MasimoInnovates | #Masimo | @0X2020 |
#United4Oxygen | #CGI2016 | #UNGA | #globalgoals
References
- Kuti BP et al. Determinants of oxygen
therapy in childhood pneumonia in a resource-constrained region.
ISRN Pediatr. 2013 Jun 2;2013:435976.
- Rudan I, et al. Epidemiology and
etiology of childhood pneumonia. Bull World Health Organ. 2008 May;
86(5): 408–416.
- Floyd, et al. Evaluating the Impact of
pulse oximetry on childhood pneumonia mortality in resource-poor
settings. Nature. 528, S53-S59 (3 December 2015).
About Masimo
Masimo (NASDAQ: MASI) is a global leader in innovative
noninvasive monitoring technologies. Our mission is to improve
patient outcomes and reduce the cost of care by taking noninvasive
monitoring to new sites and applications. In 1995, the company
debuted Masimo SET® Measure-through Motion and Low Perfusion™ pulse
oximetry, which has been shown in multiple studies to significantly
reduce false alarms and accurately monitor for true alarms. Masimo
SET® is estimated to be used on more than 100 million patients in
leading hospitals and other healthcare settings around the world.
In 2005, Masimo introduced rainbow® Pulse CO-Oximetry technology,
allowing noninvasive and continuous monitoring of blood
constituents that previously could only be measured invasively,
including total hemoglobin (SpHb®), oxygen content (SpOC™),
carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), and more
recently, Pleth Variability Index (PVI®) and Oxygen Reserve Index
(ORI™), in addition to SpO2, pulse rate, and perfusion index (PI).
In 2014, Masimo introduced Root®, an intuitive patient monitoring
and connectivity platform with the Masimo Open Connect™ (MOC-9™)
interface. Masimo is also taking an active leadership role in
mHealth with products such as the Radius-7™ wearable patient
monitor and the MightySat™ fingertip pulse oximeter. Additional
information about Masimo and its products may be found at
www.masimo.com. All published clinical studies on Masimo products
can be found at
http://www.masimo.com/cpub/clinical-evidence.htm.
Forward-Looking Statements
This press release includes forward-looking statements as
defined in Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934, in connection with the
Private Securities Litigation Reform Act of 1995. These
forward-looking statements are based on current expectations about
future events affecting us and are subject to risks and
uncertainties, all of which are difficult to predict and many of
which are beyond our control and could cause our actual results to
differ materially and adversely from those expressed in our
forward-looking statements as a result of various risk factors,
including, but not limited to: risks related to our assumptions
regarding the repeatability of clinical results; risks related to
our belief that Masimo's unique noninvasive measurement
technologies contribute to positive clinical outcomes and patient
safety; risks related to our belief that Masimo noninvasive medical
breakthroughs provide cost-effective solutions and unique
advantages; as well as other factors discussed in the "Risk
Factors" section of our most recent reports filed with the
Securities and Exchange Commission ("SEC"), which may be obtained
for free at the SEC's website at www.sec.gov. Although we believe
that the expectations reflected in our forward-looking statements
are reasonable, we do not know whether our expectations will prove
correct. All forward-looking statements included in this press
release are expressly qualified in their entirety by the foregoing
cautionary statements. You are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of today's date. We do not undertake any obligation to update,
amend or clarify these statements or the "Risk Factors" contained
in our most recent reports filed with the SEC, whether as a result
of new information, future events or otherwise, except as may be
required under the applicable securities laws.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160924005024/en/
MasimoEvan Lamb, 949-396-3376elamb@masimo.com
Masimo (NASDAQ:MASI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Masimo (NASDAQ:MASI)
Historical Stock Chart
From Sep 2023 to Sep 2024